🇺🇸 FDA
Patent

US 11161906

Multispecific antibodies, multispecific activatable antibodies and methods of using the same

granted A61PA61P35/00

Quick answer

US patent 11161906 (Multispecific antibodies, multispecific activatable antibodies and methods of using the same) held by CytomX Therapeutics, Inc. expires Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CytomX Therapeutics, Inc.
Grant date
Tue Nov 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
45
CPC classes
A61P, A61P35/00